Acute healthcare utilization in end-of-life among Swedish brain tumor patients - a population based register study.


Journal

BMC palliative care
ISSN: 1472-684X
Titre abrégé: BMC Palliat Care
Pays: England
ID NLM: 101088685

Informations de publication

Date de publication:
23 Jul 2022
Historique:
received: 14 12 2021
accepted: 11 07 2022
entrez: 22 7 2022
pubmed: 23 7 2022
medline: 27 7 2022
Statut: epublish

Résumé

Patients with progressive primary brain tumors commonly develop a spectrum of physical as well as cognitive symptoms. This places a large burden on family members and the condition's complexity often requires frequent health care contacts. We investigated potential associations between sociodemographic or socioeconomic factors, comorbidity or receipt of specialized palliative care (SPC) and acute healthcare utilization in the end-of-life (EOL) phase. A population-based retrospective study of all adult patients dying with a primary malignant brain tumor as main diagnosis in 2015-2019 in the Stockholm area, the most densely populated region in Sweden (N = 780). Registry data was collected from the Stockholm Region´s central data warehouse (VAL). Outcome variables included emergency room (ER) visits or hospitalizations in the last month of life, or death in acute hospitals. Possible explanatory variables included age, sex, living arrangements (residents in nursing homes versus all others), Charlson Comorbidity Index, socio-economic status (SES) measured by Mosaic groups, and receipt of SPC in the last three months of life. T-tests or Wilcoxon Rank Sum tests were used for comparisons of means of independent groups and Chi-square test for comparison of proportions. Associations were tested by univariable and multivariable logistic regressions calculating odds ratios (OR). The proportion of patients receiving SPC increased gradually during the last year of life and was 77% in the last 3 months of life. Multivariable analyses showed SPC to be equal in relation to sex and SES, and inversely associated with age (p ≤ 0.01), comorbidity (p = 0.001), and nursing home residency (p < 0.0001). Unplanned ER visits (OR 0.41) and hospitalizations (OR 0.45) during the last month of life were significantly less common among patients receiving SPC, in multivariable analysis (p < 0.001). In accordance, hospital deaths were infrequent in patients receiving SPC (2%) as compared to one in every four patients without SPC (p < 0.0001). Patients with less comorbidity had lower acute healthcare utilization in the last month of life (OR 0.35 to 0.65), whereas age or SES was not significantly associated with acute care utilization. Female sex was associated with a lower likelihood of EOL hospitalization (OR 0.72). Nursing home residency was independently associated with a decreased likelihood of EOL acute healthcare utilization including fewer hospital deaths (OR 0.08-0.54). Receipt of SPC or nursing home residency was associated with lower acute health care utilization among brain tumor patients. Patients with more severe comorbidities were less likely to receive SPC and required excess acute healthcare in end-of-life and therefore constitute a particularly vulnerable group.

Sections du résumé

BACKGROUND BACKGROUND
Patients with progressive primary brain tumors commonly develop a spectrum of physical as well as cognitive symptoms. This places a large burden on family members and the condition's complexity often requires frequent health care contacts. We investigated potential associations between sociodemographic or socioeconomic factors, comorbidity or receipt of specialized palliative care (SPC) and acute healthcare utilization in the end-of-life (EOL) phase.
METHODS METHODS
A population-based retrospective study of all adult patients dying with a primary malignant brain tumor as main diagnosis in 2015-2019 in the Stockholm area, the most densely populated region in Sweden (N = 780). Registry data was collected from the Stockholm Region´s central data warehouse (VAL). Outcome variables included emergency room (ER) visits or hospitalizations in the last month of life, or death in acute hospitals. Possible explanatory variables included age, sex, living arrangements (residents in nursing homes versus all others), Charlson Comorbidity Index, socio-economic status (SES) measured by Mosaic groups, and receipt of SPC in the last three months of life. T-tests or Wilcoxon Rank Sum tests were used for comparisons of means of independent groups and Chi-square test for comparison of proportions. Associations were tested by univariable and multivariable logistic regressions calculating odds ratios (OR).
RESULTS RESULTS
The proportion of patients receiving SPC increased gradually during the last year of life and was 77% in the last 3 months of life. Multivariable analyses showed SPC to be equal in relation to sex and SES, and inversely associated with age (p ≤ 0.01), comorbidity (p = 0.001), and nursing home residency (p < 0.0001). Unplanned ER visits (OR 0.41) and hospitalizations (OR 0.45) during the last month of life were significantly less common among patients receiving SPC, in multivariable analysis (p < 0.001). In accordance, hospital deaths were infrequent in patients receiving SPC (2%) as compared to one in every four patients without SPC (p < 0.0001). Patients with less comorbidity had lower acute healthcare utilization in the last month of life (OR 0.35 to 0.65), whereas age or SES was not significantly associated with acute care utilization. Female sex was associated with a lower likelihood of EOL hospitalization (OR 0.72). Nursing home residency was independently associated with a decreased likelihood of EOL acute healthcare utilization including fewer hospital deaths (OR 0.08-0.54).
CONCLUSIONS CONCLUSIONS
Receipt of SPC or nursing home residency was associated with lower acute health care utilization among brain tumor patients. Patients with more severe comorbidities were less likely to receive SPC and required excess acute healthcare in end-of-life and therefore constitute a particularly vulnerable group.

Identifiants

pubmed: 35869460
doi: 10.1186/s12904-022-01022-2
pii: 10.1186/s12904-022-01022-2
pmc: PMC9308283
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

133

Informations de copyright

© 2022. The Author(s).

Références

Eur J Public Health. 2019 Feb 1;29(1):67-74
pubmed: 30481305
Brain Behav. 2019 Aug;9(8):e01348
pubmed: 31287226
Neuro Oncol. 2018 Feb 19;20(3):391-399
pubmed: 29016886
J Clin Oncol. 2017 Jan;35(1):96-112
pubmed: 28034065
Acta Oncol. 2022 Jul;61(7):874-880
pubmed: 35411838
BMJ. 2015 Oct 07;351:h4855
pubmed: 26446163
Neurooncol Pract. 2021 May 21;8(5):569-580
pubmed: 34691748
BMC Cancer. 2021 Jun 30;21(1):757
pubmed: 34187404
Eur J Cancer. 2015 Jul;51(10):1331-9
pubmed: 25958036
Patient Educ Couns. 2013 May;91(2):141-53
pubmed: 23218925
BMC Geriatr. 2016 Aug 22;16:154
pubmed: 27549203
Epidemiology. 2007 Nov;18(6):805-35
pubmed: 18049195
Ups J Med Sci. 2020 Nov;125(4):297-304
pubmed: 33100083
Acta Oncol. 2014 Feb;53(2):161-3
pubmed: 24328505
J Neurooncol. 2017 May;132(3):447-453
pubmed: 28258423
Oncologist. 2013;18(2):198-203
pubmed: 23335620
Palliat Med. 2016 Sep;30(8):745-63
pubmed: 26944531
Acta Oncol. 2020 Jun;59(6):620-627
pubmed: 32148138
Cancer Control. 2021 Jan-Dec;28:10732748211011956
pubmed: 33929888
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
BMC Pulm Med. 2021 May 19;21(1):170
pubmed: 34011344
Brain Sci. 2018 Jun 30;8(7):
pubmed: 29966347
Int J Environ Res Public Health. 2021 Jul 07;18(14):
pubmed: 34299722
BMJ Support Palliat Care. 2019 Sep 19;:
pubmed: 31537581
J Palliat Care. 2018 Apr;33(2):109-114
pubmed: 29514555
BMC Geriatr. 2017 Nov 23;17(1):271
pubmed: 29169346
J Neurooncol. 2014 Jan;116(1):119-26
pubmed: 24078175
JAMA. 2016 Jan 19;315(3):284-92
pubmed: 26784776
J Palliat Med. 2020 Mar;23(3):415-421
pubmed: 31613698
Cancer. 2019 Oct 1;125(19):3390-3400
pubmed: 31206646
BMJ Open. 2012 Aug 24;2(4):
pubmed: 22923630
Cancers (Basel). 2021 Jun 08;13(12):
pubmed: 34201260
BMJ Support Palliat Care. 2014 Mar;4(1):68-76
pubmed: 24644774
Semin Oncol Nurs. 2018 Dec;34(5):513-527
pubmed: 30424920
Nature. 2018 Sep;561(7724):S40-S41
pubmed: 30258156
Eur J Cancer. 2011 Jun;47(9):1398-406
pubmed: 21237637
Acta Oncol. 2019 Apr;58(4):432-438
pubmed: 30633611
Neurooncol Pract. 2020 Jun;7(3):288-298
pubmed: 32537178
J Neurooncol. 2014 Mar;117(1):103-15
pubmed: 24469851
BMC Palliat Care. 2021 Mar 14;20(1):43
pubmed: 33715623
BMJ Support Palliat Care. 2015 Sep;5(3):294-6
pubmed: 24644165
J Palliat Med. 2020 Nov;23(11):1460-1467
pubmed: 32286904
Basic Clin Pharmacol Toxicol. 2019 Oct;125(4):360-369
pubmed: 31188534
Br J Cancer. 2012 Jun 26;107(1):189-94
pubmed: 22576591
J Clin Oncol. 2015 Feb 1;33(4):370-6
pubmed: 25534384
Lancet Oncol. 2017 Jun;18(6):e330-e340
pubmed: 28593859
J Pain Symptom Manage. 2017 Feb;53(2):257-264
pubmed: 27810565

Auteurs

Magnus Lindskog (M)

Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden. magnus.lindskog@igp.uu.se.

Torbjörn Schultz (T)

Department, Stockholms Sjukhem Foundation, Stockholm, Sweden.

Peter Strang (P)

Department of Oncology-Pathology, R & D Department, Karolinska Institutet, Regional Cancer Centre in Stockholm - Gotland, Stockholms Sjukhem Foundation, Stockholm, Sweden.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH